Moberg Pharma AB Registered Shs News

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Strukturierte Produkte

Aktion

Portfolio

Watchlist

29.01.21	New number of shares and votes in Moberg Pharma AB (publ) (PR Newswire)
30.11.20	Moberg Pharma obtains positive decision from the Swedish Tax Agency regarding the Lex Asea distribution of the shares in OncoZenge (PR Newswire)
23.11.20	Invitation to market update in Moberg Pharma on November 25th (PR Newswire)
16.11.20	OncoZenge secures approximately SEK 70 million in financing ahead of spin-off and separate listing (PR Newswire)
14.10.20	Moberg Pharma intends to submit a registration application in Europe in 2021 (PR Newswire)
14.10.20	Moberg Pharma intends to submit a registration application in Europe in 2021 (PR Newswire)
04.08.20	Moberg Pharma's Interim report for July 2019 - June 2020 to be published on August 11 - Invitation to teleconference (PR Newswire)
30.07.20	Appointment of Chief Medical Officer at Moberg Pharma (PR Newswire)
30.06.20	New number of Shares and Votes in Moberg Pharma AB (publ) (PR Newswire)
25.06.20	Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study (PR Newswire)
25.06.20	Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study (PR Newswire)
29.05.20	New Number of Shares and Votes in Moberg Pharma AB (publ) (PR Newswire)
05.05.20	Moberg Pharma's Interim Report for July 2019 - March 2020 to be Published on May 12 - Invitation to Teleconference (PR Newswire)
11.02.20	Moberg Pharma AB Interim Report October - December 2019 (PR Newswire)
04.02.20	Moberg Pharma's Interim Report to be Published on February 11 - Invitation to Teleconference (PR Newswire)
22.01.20	Expert Evaluation Clarifies Phase 3 Results and Provides Strong Support for MOB-015 (PR Newswire)
12.12.19	Moberg Pharma Comments on the Results of the North American Phase 3 Study With MOB-015 (PR Newswire)

Newssuche

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	302.80	1.30 %	K V
Alcon	76.88	0.65 %	K V
Sika	218.00	0.37 %	K V
Kuehne+Nagel Int	202.60	-0.20 %	K V
Logitech Intl	78.28	-0.33 %	K V
ABB	49.25	-1.44 %	K V
Holcim	87.68	-1.55 %	K V
Zurich Insur Gr	531.20	-1.63 %	K V
Roche Hldg G	267.20	-1.69 %	K V
UBS Group	29.78	-1.94 %	K V